Human anti Omalizumab (Drug/Target Complex),clone AbD20760_hIgG1
文献支持

Human anti Omalizumab (Drug/Ta

rget Complex),clone AbD20760_hIgG1
收藏
  • 询价
  • BIO-RAD已认证
  • HCA237
  • 2025年10月17日
  • E
  • 详细信息
  • 文献和实验
  • 技术资料
  • 免疫原

    Omalizumab/IgE complex

  • 亚型

    IgG1

  • 形态

    Human IgG1 antibody (kappa light chain) selected from the HuCAL phage display library and expressed in a human cell line.This antibody is supplied as a liquid.

  • 克隆性

    Monoclonal Antibody

  • 标记物

    Purified

  • 保质期

    自发货之日起 12 个月

  • 目录编号

    AbD20760_hIgG1

  • 供应商

    伯乐生命医学产品(上海)有限公司

  • 应用范围

    E

  • 浓度

    IgG concentration 0.5 mg/ml

  • 抗体名

    Omalizumab antibody | AbD20760_hIgG1

  • 规格

    0.1 mg

Human anti omalizumab, clone AbD20760_hIgG1 binds specifically to the omalizumab/IgE (drug/target) complex. The antibody does not recognize free omalizumab or free human IgE. It can be used in bioanalytical assays to detect bound omalizumab or biosimilar products exclusively.

Clone AbD20760_hIgG1 can be used to develop a pharmacokinetic (PK) antigen capture assay to measure omalizumab captured via immobilized human IgE or to measure the level of drug/IgE complex in preclinical or clinical samples. This product is in a full immunoglobulin format and is available directly labeled with HRP. The antibody is also available in unlabeled Fab format (HCA238).

Omalizumab (brand name Xolair®) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.

Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit.

View a summary of all anti-omalizumab antibodies


储存信息

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.


应用

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual.
ELISA
This product may be used in a direct ELISA to detect the omalizumab/IgE complex or to detect omalizumab bound to immobilized IgE.
Protocol: PK antigen capture ELISA to measure bound drug exclusively.


风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

图标文献和实验
该产品被引用文献

References for Omalizumab antibody

  1. Harth, S. et al. (2019) Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.
    MAbs. 11 (1): 178-190.
图标技术资料

暂无技术资料 索取技术资料

同类产品报价

产品名称
产品价格
公司名称
报价日期
询价
伯乐生命医学产品(上海)有限公司 Bio-Rad Laboratories
2025年10月17日询价
¥8343.92
深圳欣博盛生物科技有限公司
2025年10月06日询价
¥1792
广州市左克生物科技发展有限公司
2025年09月02日询价
¥4080
武汉佰乐博生物技术有限公司
2025年07月15日询价
¥2108
普健生物(武汉)科技有限公司
2025年07月12日询价
文献支持
Human anti Omalizumab (Drug/Target Complex),clone AbD20760_hIgG1
询价